Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells

Area of Science:

• Immunology
• Oncology
• Vaccine Development

Background:

• Early-phase trials show synergy between HER2-derived peptide vaccines and trastuzumab in HER2+ breast cancer patients.
• No recurrences observed in patients vaccinated after trastuzumab treatment in clinical trials.
• Trastuzumab is a monoclonal antibody targeting the HER2 protein.

Purpose of the Study:

• To elucidate the mechanism behind the synergistic effect of trastuzumab and HER2 peptide vaccines.
• To investigate how trastuzumab influences the immune response in HER2+ breast cancer.

Main Methods:

• Flow cytometry to assess HER2 uptake by dendritic cells (DCs) mediated by trastuzumab.
• In vitro and in vivo mouse models to evaluate the cross-presentation of the E75 epitope.
• Analysis of E75-specific cytotoxic T cell (E75-CTL) expansion.

Main Results:

• Trastuzumab facilitates Fc receptor-mediated uptake of HER2 by DCs.
• Increased HER2 uptake by DCs enhances the cross-presentation of the E75 epitope.
• Trastuzumab treatment leads to more efficient expansion of E75-specific CTLs.

Conclusions:

• Trastuzumab links innate and adaptive immunity by facilitating antigen-specific T cell activation.
• HER2-positive breast cancer patients treated with trastuzumab may achieve a more robust antitumor response with E75 peptide vaccination.
• The findings explain the improved disease-free survival observed with combination therapy.